Методологични въпроси при измерване на ефективността на разходите в здравеопазването
Keywords:
разходи, анализ на разходи, оценка на здравни технологии, разходна ефективност
Abstract
Изследванията върху разходите и свързаните с тях здравни ползи са основна част от управленския процес в здравеопазването. Интересът към този вид анализи е преди всичко свързан с опасенията за нарастващите разходи и натиска върху здравните власти да разпределят ресурси за ефективното използване на иновативни здравни технологии. Надеждността на резултатите, получени от тези анализи, зависи до голяма степен от правилното прилагане на различните подходи и разбирането на техните специфики.
References
Драмънд, МФ, О’Брайън Б, Стодарт ГЛ, Торънс ДУ. Методи за икономическа оценка на здравни програми. Медицина и физкултура, София, 2007.
Гладилов С, Делчева Е. Икономика на здравеопазването. Princeps, София, 2009.
Goodman CS. Introduction to health technology assessment. The Lewin Group. Virginia, USA, 2004.
Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health. 2009 Dec;6(12):2950-66.
Jakovljevic MM, Pejcic AV. Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight. Front Public Health. 2017 Aug 11;5:211.
Schwarzer R, Siebert U. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. Int J Technol Assess Health Care. 2009 Jul;25(3):305-14.
Velasco-Garrido M, Busse R. Health technology assessment: an introduction to objectives, role of evidence, and structure in Europe. Copenhagen, World Health Organization Regional Office for Europe, on behalf of the European Observatory on Health Systems and Policies, 2005.
Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014 Mar;23(2):413-23.
Dehnavieh R, Hekmat SN, Ghasemi S, Mirshekari N. The vulnerable aspects of application of “Health Technology Assessment”. Int J Technol Assess Health Care. 2015 Jan;31(3):197-8.
Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004;13:437-452.
Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel-Nazco C, García-Pérez L, Linertová R, Polentinos-Castro E, Serrano-Aguilar P. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? Value Health. 2016 Jul-Aug;19(5):558-66.
Buxton MJ, Drummond MF, van Hout B, Prince RL, Sheldon TA, Szucs T, Vray M. Modeling in economic evaluation: an unavoidable fact of life. Health Economics 1997;6;217-27.
Brooks R. EuroQoL: the current state of play. Health Policy 1996;37:53-72.
Owen L, Pennington B, Fischer A, Jeong K. The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016. J Public Health (Oxf). 2017 Sep 18:1-10.
Slomiany M, Madhavan P, Kuehn M, Richardson S. Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry. Am Health Drug Benefits. 2017 Jul;10(5):253-260.
Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, König HH. Calculation of standardised unit costs from a societal perspective for health economic evaluation. Gesundheitswesen. 2015 Jan;77(1):53-61. [Article in German]
Heilmann C. Values in Time Discounting. Sci Eng Ethics. 2017 Aug 15.
Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics. 2005;23(7):639-49.
López-Bastida J, Oliva-Moreno J, Linertová R, Serrano-Aguilar P. Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016 Apr;17 Suppl 1:1-5.
Kigozi J, Jowett S, Lewis M, Barton P, Coast J. The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review. Value Health. 2017 Mar;20(3):496-506.
Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013 Jul;31(7):537-49.
Гладилов С, Делчева Е. Икономика на здравеопазването. Princeps, София, 2009.
Goodman CS. Introduction to health technology assessment. The Lewin Group. Virginia, USA, 2004.
Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health. 2009 Dec;6(12):2950-66.
Jakovljevic MM, Pejcic AV. Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight. Front Public Health. 2017 Aug 11;5:211.
Schwarzer R, Siebert U. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. Int J Technol Assess Health Care. 2009 Jul;25(3):305-14.
Velasco-Garrido M, Busse R. Health technology assessment: an introduction to objectives, role of evidence, and structure in Europe. Copenhagen, World Health Organization Regional Office for Europe, on behalf of the European Observatory on Health Systems and Policies, 2005.
Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014 Mar;23(2):413-23.
Dehnavieh R, Hekmat SN, Ghasemi S, Mirshekari N. The vulnerable aspects of application of “Health Technology Assessment”. Int J Technol Assess Health Care. 2015 Jan;31(3):197-8.
Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004;13:437-452.
Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel-Nazco C, García-Pérez L, Linertová R, Polentinos-Castro E, Serrano-Aguilar P. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? Value Health. 2016 Jul-Aug;19(5):558-66.
Buxton MJ, Drummond MF, van Hout B, Prince RL, Sheldon TA, Szucs T, Vray M. Modeling in economic evaluation: an unavoidable fact of life. Health Economics 1997;6;217-27.
Brooks R. EuroQoL: the current state of play. Health Policy 1996;37:53-72.
Owen L, Pennington B, Fischer A, Jeong K. The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016. J Public Health (Oxf). 2017 Sep 18:1-10.
Slomiany M, Madhavan P, Kuehn M, Richardson S. Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry. Am Health Drug Benefits. 2017 Jul;10(5):253-260.
Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, König HH. Calculation of standardised unit costs from a societal perspective for health economic evaluation. Gesundheitswesen. 2015 Jan;77(1):53-61. [Article in German]
Heilmann C. Values in Time Discounting. Sci Eng Ethics. 2017 Aug 15.
Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics. 2005;23(7):639-49.
López-Bastida J, Oliva-Moreno J, Linertová R, Serrano-Aguilar P. Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016 Apr;17 Suppl 1:1-5.
Kigozi J, Jowett S, Lewis M, Barton P, Coast J. The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review. Value Health. 2017 Mar;20(3):496-506.
Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013 Jul;31(7):537-49.
Published
2017-09-15
How to Cite
1.
Искров Г, Митева-Катранджиева Ц, Стефанов Р. Методологични въпроси при измерване на ефективността на разходите в здравеопазването. Редки болести и лекарства сираци [Internet]. 2017Sep.15 [cited 2024Dec.30];8(3):17-2. Available from: https://journal.raredis.org/index.php/RBLS/article/view/25
Issue
Section
Статии
Съдържанието е достъпно под лиценза Creative Commons Attribution-NonCommercial 4.0 International License.
